Novel therapies for pancreatic cancer: Setbacks and progress

Future Oncology

Volumn 6, Issue 7, 2010, Pages 1061-1064

  Wong, Han Hsi ^a   Lemoine, Nicholas R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; BEVACIZUMAB; BORTEZOMIB; CALAA 01; CELECOXIB; CYCLIN G1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GASTRAZOLE; GASTRIN 17; GEMCITABINE; GENDICINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GV 1001; MARIMASTAT; MICRORNA; ONCOVEX; ONYX 015; PEPTIDE VACCINE; RETROVIRUS VECTOR; REXIN G; SMALL INTERFERING RNA; TANOMASTAT; TELOMERASE; TIPIFARNIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER THERAPY; EDITORIAL; GENE THERAPY; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RASH; SURVIVAL RATE; ANALOGS AND DERIVATIVES; DRUG DELIVERY SYSTEM; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRENDS;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77954679120     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.70     Document Type: Editorial

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Wong HH, Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 6(7), 412-422 (2009).
3. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
4. Philip PA, Benedetti J, Fenoglio-Preiser C, et al.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J. Clin. Oncol. (Meeting Abstracts) 25(18 Suppl.), (2007) (Abstract 4509).
5. Buanes T, Maurel J, Liauw W, Hebbar M, Nemunaitis J: A randomized Phase III study of gemcitabine (G) versus GV1001 in sequential combination with g in patients with unresectable and metastatic pancreatic cancer (PC). J. Clin. Oncol. (Meeting Abstracts) 27(15 Suppl.), (2009) (Abstract 4601).
6. Olive KP, Jacobetz MA, Davidson CJ, et al.: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457-1461 (2009).
7. Alberts SR, Foster NR, Morton RF, et al.: PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized Phase II study. Ann. Oncol. 16(10), 1654-1661 (2005).
8. Sloss CM, Wang F, Liu R, et al.: Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 14(16), 5116-5123 (2008).
9. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schonthal AH: COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol. Cancer 7, 38 (2008).
10. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
11. Wong HH, Lemoine NR: Biological approaches to therapy of pancreatic cancer. Pancreatology 8(4-5), 431-461 (2008).
12. Chawla SP, Chua VS, Fernandez L, et al.: Advanced Phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol. Ther. 18(2), 435-441 (2010).
13. Mulvihill S, Warren R, Venook A, et al.: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replicationselective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. 8(4), 308-315 (2001).
14. Hecht JR, Bedford R, Abbruzzese JL, et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9(2), 555-561 (2003).
15. Wong HH, Lemoine NR, Wang Y: Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2(1), 78-106 (2010).
16. Wang Y, Gangeswaran R, Zhao X, et al.: CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J. Clin. Invest. 119(6), 1604-1615 (2009).
17. Nishimoto T, Yoshida K, Miura Y, et al.: Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Gene Ther. 16(5), 669-680 (2009).
18. Hiley CT, Yuan M, Lemoine NR, Wang Y: Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 17(2), 281-287 (2010).
19. Tysome JR, Briat A, Alusi G, et al.: Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 16(10), 1223-1233 (2009).
20. Hirano S, Etoh T, Okunaga R, et al.: Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model. Oncol. Rep. 21(6), 1381-1384 (2009).
21. Zhang Z, Huang Y, Newman K, et al.: Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Clin. Cancer Res. 15(16), 5154-5160 (2009).
22. Bortolanza S, Bunuales M, Otano I, et al.: Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in syrian hamsters. Mol. Ther. 17(4), 614-622 (2009).
23. Leitner S, Sweeney K, Oberg D, et al.: Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin. Cancer Res. 15(5), 1730-1740 (2009).
24. Nelson AR, Davydova J, Curiel DT, Yamamoto M: Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci. 100(11), 2181-2187 (2009).
25. Watanabe I, Kasuya H, Nomura N, et al.: Effects of tumor selective replicationcompetent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother. Pharmacol. 61(5), 875-882 (2008).
26. Alberts SR, Schroeder M, Erlichman C, et al.: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II trial. J. Clin. Oncol. 22(24), 4944-4950 (2004).
27. Rejiba S, Wack S, Aprahamian M, Hajri A: K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 98(7), 1128-1136 (2007).
28. Chen C, Yu Z: siRNA targeting HIF-1a induces apoptosis of pancreatic cancer cells through NF-kB-independent and -dependent pathways under hypoxic conditions. Anticancer Res. 29(4), 1367-1372 (2009).
29. Li M, Zhang Y, Bharadwaj U, et al.: Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin. Cancer Res. 15(19), 5993-6001 (2009).
30. Li M, Zhang Y, Liu Z, et al.: Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc. Natl Acad. Sci. USA 104(47), 18636-18641 (2007).
31. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH: Down-regulation of notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 5(3), 483-493 (2006).
32. Yang G, Huang C, Cao J, Huang KJ, Jiang T, Qiu ZJ: Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion. World J. Gastroenterol. 15(30), 3757-3766 (2009).
33. Lee EJ, Gusev Y, Jiang J, et al.: Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046-1054 (2007). (Pubitemid 46214304)
34. Li Y, Vandenboom TG 2nd, Wang Z, et al.: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70(4), 1486-1495 (2010).
35. Ji Q, Hao X, Zhang M, et al.: MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4(8), E6816 (2009).
36. Kallifatidis G, Beckermann BM, Groth A, et al.: Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Ther. 15(4), 231-240 (2008).